1. Heterogeneous nuclear ribonucleoprotein M promotes the progression of breast cancer by regulating the axin/β-catenin signaling pathway
- Author
-
Mingjian Ding, Meng Yang, Wenhua Yang, Guozhong Cui, and Dian-Lu Dai
- Subjects
0301 basic medicine ,Cell signaling ,Beta-catenin ,Breast Neoplasms ,Mice, SCID ,Mice ,03 medical and health sciences ,0302 clinical medicine ,Cyclin D1 ,Breast cancer ,Axin Protein ,Biomarkers, Tumor ,medicine ,Animals ,Humans ,beta Catenin ,Pharmacology ,biology ,Cell growth ,Wnt signaling pathway ,General Medicine ,medicine.disease ,Xenograft Model Antitumor Assays ,Heterogeneous-Nuclear Ribonucleoprotein Group M ,Mice, Inbred C57BL ,030104 developmental biology ,030220 oncology & carcinogenesis ,Disease Progression ,MCF-7 Cells ,biology.protein ,Cancer research ,Female ,Signal transduction ,Signal Transduction - Abstract
Despite significant progress in the treatment of breast cancer due to advances in surgery, cytotoxic agents, and endocrine therapy, the prognosis for patients has not improved much. Accumulated evidence indicates that heterogeneous nuclear ribonucleoprotein M (hnRNPM) and Wnt/β-catenin function as tumor oncogenes in the progression of many cancers. The present study aimed to explore whether HnRNPM/β-catenin signaling molecules might serve as a genetic target for breast cancer treatment. To shed light on this issue, quantitative real-time polymerase chain reaction (qRT-PCR) detection, Western blotting, and immunohistochemical staining were performed. The hnRNPM is expressed at a much higher level in breast cancer tissues and cell lines than in noncancerous tissues and cell lines. In vitro studies revealed that overexpressed hnRNPM promoted cell proliferation and colony formation but inhibited cell apoptosis. In vivo results demonstrated that upregulation of hnRNPM dramatically increased breast cancer xenograft tumor growth. Western blotting and immunofluorescence studies revealed that hnRNPM markedly activated the Wnt/β-catenin pathway and catalyzed its translocation from the cytoplasm to the nucleus by targeting axin, a negative regulator of Wnt/β-catenin signaling in MCF-7 and KPL-4 cells. Elevated levels of c-Myc and cyclin D1 were observed when MCF-7 and KPL-4 cells were transfected with a hnRNPM vector. These findings indicate that the hnRNPM/axin/β-catenin signaling pathway acts as an oncogenic promoter in the progression of breast cancer, suggesting that hnRNPM may be a potential target for the treatment of this disease.
- Published
- 2018